(IN BRIEF) Recent studies suggest that current cardiovascular risk assessment methods may be inadequate and call for a more personalized approach. Tools like carotid ultrasound offer promising solutions for more precise evaluations, enabling targeted interventions such as aspirin therapy, which … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged aspirin therapy, Bayer, cardiovascular disease, cardiovascular health, Cardiovascular risk, carotid ultrasound, coronary artery calcium scoring, Dr. Michael Blaha, Dr. Ricardo Salazar, healthcare access, heart disease prevention, ischemic events, medical research, personalized medicine, risk assessment, stroke prevention, subclinical atherosclerosis, subclinical plaque
(IN BRIEF) Bayer and Evotec have updated their strategic collaboration to focus on developing precision treatments for cardiovascular diseases (CVDs). Leveraging Evotec’s expertise in disease modelling using human induced pluripotent stem cells (iPSCs), the collaboration aims to identify and validate … Read the full press release
Posted in Business, Education, Environment, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Bayer, Cardiovascular Therapies, Dr Cord Dohrmann, Dr. Christian Rommel, Evotec, Juergen Eckhardt, partnership, sustainability
(IN BRIEF) Bayer has invested $250 million in a new cell therapy production plant in Berkeley, California, USA. This investment aims to support the production of materials for clinical trials and potential commercial launches of BlueRock Therapeutics’ bemdaneprocel (BRT-DA01), an … Read the full press release
Posted in Business, Environment, Financial, Germany, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, News, Pharma & Biotech, Science
Tagged Bayer, Bemdaneprocel, Berkeley, BRT-DA01, California, Cell Therapy Plant, Holger Weintritt, Parkinson's disease, partnership, Seth Ettenberg, Stefan Oelrich, sustainability, USA
(IN BRIEF) Bayer is making a significant investment of EUR 220 million in research and development (R&D) at its Monheim site in Germany, focusing on its Crop Protection business. This represents the company’s largest single investment in Crop Protection in … Read the full press release
Posted in Agriculture, Business, Education, Environment, Financial, Germany, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Bayer, crop protection, Dr. Axel Trautwein, Dr. Robert Reiter, INNOVATION, investment, Rachel Rama, Regenerative Agriculture, sustainability
(IN BRIEF) Pairwise and Bayer have entered into a new five-year, multi-million Dollar collaboration focusing on gene-edited short-stature corn. Building on their initial partnership for corn, soy, wheat, cotton, and canola, this collaboration aims to optimize and enhance gene-edited short-stature … Read the full press release
Posted in Agriculture, Business, Environment, Germany, Industrial, Management, News, Pharma & Biotech
Tagged Bayer, Bob Reiter, Gene-Edited Short-Stature Corn, Pairwise, partnership, Smart Agriculture, sustainability, Tom Adams
(IN BRIEF) BlueRock Therapeutics and bit.bio have announced a collaboration and option agreement to discover and manufacture iPSC-derived regulatory T cells (Tregs) for therapeutic use. Tregs are crucial for immune system balance and controlling excessive immune reactions, making them potential … Read the full press release
Posted in Business, Education, Germany, Healthcare, Management, News, Pharma & Biotech, Science
Tagged Autoimmune Disorders, Bayer, bit.bio, bit.bio’s opti-ox™, BlueRock Therapeutics, iPSC, Mark Kotter, partnership, Stefan Irion, T Cell Therapies, Tregs
(IN BRIEF) Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company owned by Bayer AG, has begun the Phase 1/Phase 2 LION-CS101 clinical trial for patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The trial is evaluating AB-1003 (LION-101), an investigational … Read the full press release
Not intended for U.S. and UK Media (IN BRIEF) Bayer AG has partnered with Acuitas Therapeutics, Inc. to enhance its gene therapy portfolio. Acuitas’ lipid nanoparticle (LNP) delivery technology will enable targeted and efficient delivery of gene editing RNA components … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech
Tagged Acuitas Therapeutics, AskBio, Asklepios BioPharmaceutical, Bayer, Clinically validated, components, DNA, Dr. Thomas Madden, Friedemann Janus, gene editing, gene therapy, High potency ionizable lipid technology, Jost Reinhardt, lipid nanoparticle, LNP, LNP carriers, messenger RNA, molecular therapeutics, mRNA, RNA, vivo gene editing
Not intended UK Media (IN BRIEF) Bayer and Cedilla Therapeutics have entered into an exclusive license agreement to develop and commercialize Cedilla’s CyclinE1/CDK2 complex inhibitors for precision oncology. These inhibitors target oncogenic drivers and offer a unique method of action, … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech
Tagged Bayer, CDK2, CDK2 inhibitors, Cedilla, Cedilla Therapeutics, Cyclin Dependent Kinase 2, cyclin E, CyclinE1, CyclinE1/CDK2 complex inhibitors, Dominik Ruettinger, Exclusive license agreement, M.D., Neil Exter, oncogenic drivers, Ph.D., precision oncology
(IN BRIEF) Bayer has announced the recipients of its 2023 Grants4Ag program, which will provide funding and mentorship to researchers working on sustainability and biotechnology in agriculture. The program will award grants ranging from €5,000 to €15,000 and connect researchers … Read the full press release
Posted in Agriculture, Awards, Business, Germany, Management, News, Pharma & Biotech, Science, Technology
Tagged agriculture, Awards, Bayer, biotechnology, Dr. Phil Taylor, grants, Grants4Ag program, innovative, mentorship, Prof. Ji Zhou, researchers, sustainability
(NOTIZIA IN BREVE) Bayer, la società di scienze della vita, ha annunciato un investimento di 60 milioni di euro nel suo impianto di produzione di semi di mais a Pochuiky, in Ucraina, per rafforzare la sua attività di Crop Science … Read the full press release
Posted in Agriculture, Germany, Investment, Ukraine
Tagged agricoltori ucraini, attrezzature agricole, Bayer, essiccatoio di semi, impianti di stoccaggio, Matthias Berninger, Oliver Gierlichs, Pochuiky, produzione di semi di mais, rifugi antiaerei, Robert Habeck, scienza delle colture, scienze della vita, Ucraina
(IN BRIEF) Bayer, the life sciences company, has announced a €60 million investment in its corn seed production facility in Pochuiky, Ukraine, to strengthen its Crop Science business and contribute to rebuilding the economy of the country. The investment includes … Read the full press release
(IN BRIEF) Siemens has supplied Bayer’s Crop Science Division with pressure transmitters containing standardized ID links, enabling the transfer of digital documentation in real time to the ERP system used by the customer. The transmitters feature technology that complies with … Read the full press release
(IN BRIEF) Bayer has launched a new water strategy at the UN 2023 Water Conference in New York, which aims to make water an integral part of its business decisions, investments, and supplier selection. The strategy reflects the company’s role … Read the full press release
Posted in Agriculture, Chemicals, Environment, Germany, Healthcare, Management, News, Pharma & Biotech, Technology
Tagged agriculture, Bayer, Corporate Water Stewardship, Cristina Alonso Alija, health, Werner Baumann
(NOTICIA EN BREVE) Bayer y la empresa francesa M2i Group se unen para ofrecer soluciones de protección de cultivos basadas en feromonas a los productores de frutas y verduras de todo el mundo. Bayer se convertirá en distribuidor exclusivo de … Read the full press release
Posted in Agriculture, Business, Environment, France, Germany, News, Science
Tagged Bayer, biodiversidad, cultivos, feromonas, Feromonas biológicas, Jens Hartmann, M2i, M2i Group, no tóxicas, Philippe Guerret, piretro natural, plagas de lepidópteros, polinizadores, protección biológica de cultivos, protección biológica de cultivos basada en feromonas, Vynyty Citrus®
(IN BRIEF) Bayer and French firm M2i Group team up to offer pheromone-based crop protection solutions to fruit and veggie growers globally. Bayer to become exclusive distributor of select M2i products aimed at Lepidoptera pests in crops such as tomatoes, … Read the full press release
Posted in Agriculture, Business, Environment, France, Germany, News, Science
Tagged Bayer, biodiversity, biological crop protection, Biological pheromones, crops, Jens Hartmann, lepidoptera pests, M2i, M2i Group, natural pyrethrum, non-toxic, pheromone-based biological crop protection, pheromones, Phillippe Guerret, pollinators, Vynyty Citrus®
Non destinato ai media statunitensi e britannici (NOTIZIA IN BREVE) Il comitato per i medicinali per uso umano dell’Agenzia europea per i medicinali ha raccomandato l’autorizzazione all’immissione in commercio nell’Unione europea di darolutamide, un inibitore orale del recettore degli androgeni, … Read the full press release
Posted in European Union, Germany, Healthcare, News, Pharma & Biotech
Tagged ADT, Agenzia europea per i medicinali, Bayer, carcinoma prostatico, carcinoma prostatico sensibile agli ormoni metastatico, CHMP, Christine Roth, Commissione europea, darolutamide, docetaxel, inibitore, mHSP, nmCRPC, Nubeqa™, Prof. Bertrand Tombal, terapia di privazione degli androgeni
Not intended for U.S. and UK Media (IN BRIEF) The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended darolutamide, an oral androgen receptor inhibitor, for marketing authorization in the European Union as a treatment for patients … Read the full press release
Posted in European Union, Germany, Healthcare, News, Pharma & Biotech
Tagged ADT, androgen deprivation therapy, Bayer, CHMP, Christine Roth, darolutamide, docetaxel, European Commission, European Medicines Agency, inhibitor, metastatic hormone-sensitive prostate cancer, mHSP, nmCRPC, Nubeqa™, Prof. Bertrand Tombal, prostate cancer
(PRESS RELEASE) SAN SEBASTIAN, Spain, 9-Jan-2023 — /EuropaWire/ — Bayer (ETR: BAYN), a global enterprise with core competencies in the life science fields of healthcare and nutrition and and one of the largest pharmaceutical companies in the world, has announced … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Spain
Tagged analytical development, Asklepios BioPharmaceutical, Bayer, Certified Good Manufacturing Practices (cGMP), commercial manufacturing, contract development and manufacturing organization (CDMO), European Medicines Agency (EMA), gene therapies, Javier García, Jimmy Vanhove, manufacturing capacity, quality control labs, recombinant adeno-associated virus (rAAV), science and technology (MSAT), single-use bioreactors, Spanish Agency for Medicines and Medical Devices (AEMPS), Viralgen Vector Core
(COMUNICADO DE PRENSA) SAN SEBASTIAN, Spain, 9-Jan-2023 — /EuropaWire/ — Bayer (ETR: BAYN), una empresa global con competencias básicas en los campos de las ciencias biológicas de la salud y la nutrición y una de las compañías farmacéuticas más grandes … Read the full press release
Posted in Germany, Healthcare, News, Pharma & Biotech, Spain
Tagged Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Agencia Europea del Medicamento (EMA), Asklepios BioPharmaceutical, Bayer, biorreactores de un solo uso, Buenas Prácticas de Fabricación Certificadas (cGMP), capacidad de fabricación, ciencia y tecnología (MSAT), desarrollo analítico, fabricación comercial, Javier García, Jimmy Vanhove, laboratorios de control de calidad, organización de fabricación y desarrollo por contrato (CDMO), terapias génicas, Viralgen Vector Core, virus recombinante adenoasociado ( rAAV)
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?